

Swarnlata Saraf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7357033/publications.pdf>

Version: 2024-02-01

19
papers

2,287
citations

430754

18
h-index

839398

18
g-index

19
all docs

19
docs citations

19
times ranked

3318
citing authors

#	ARTICLE	IF	CITATIONS
1	Approaches for breaking the barriers of drug permeation through transdermal drug delivery. Journal of Controlled Release, 2012, 164, 26-40.	4.8	401
2	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release, 2018, 281, 139-177.	4.8	377
3	Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. Journal of Controlled Release, 2017, 260, 61-77.	4.8	251
4	Cubosomes: An Overview. Biological and Pharmaceutical Bulletin, 2007, 30, 350-353.	0.6	209
5	Polyethylene glycol (PEG)â€“Poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 575-585.	2.0	161
6	Poly(ethylene glycol)â€“poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications. Journal of Controlled Release, 2013, 172, 715-729.	4.8	150
7	Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. Journal of Controlled Release, 2020, 327, 235-265.	4.8	137
8	Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. Journal of Controlled Release, 2020, 321, 372-415.	4.8	132
9	Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. Journal of Controlled Release, 2016, 241, 110-124.	4.8	114
10	Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opinion on Drug Delivery, 2018, 15, 589-617.	2.4	74
11	Recent approaches for reducing hemolytic activity of chemotherapeutic agents. Journal of Controlled Release, 2015, 211, 10-21.	4.8	46
12	Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2019, 39, 181-209.	1.7	44
13	Insulin mediated novel therapies for the treatment of Alzheimer's disease. Life Sciences, 2020, 249, 117540.	2.0	41
14	Luteolin-phospholipid complex: preparation, characterization and biological evaluation. Journal of Pharmacy and Pharmacology, 2014, 66, 1451-1462.	1.2	39
15	A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates. Drug Development and Industrial Pharmacy, 2015, 41, 1954-1961.	0.9	28
16	Exploring the role of polymeric conjugates toward anti-cancer drug delivery: Current trends and future projections. International Journal of Pharmaceutics, 2018, 548, 500-514.	2.6	27
17	Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate. Journal of Pharmacy and Pharmacology, 2014, 66, 1240-1250.	1.2	25
18	Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate. Current Drug Delivery, 2016, 13, 621-630.	0.8	19

#	ARTICLE	IF	CITATIONS
19	Nose-to-brain drug delivery. , 2020, , 175-200.		12